AB198878

Anti-CTAG1B antibody

Be the first to review this product! Submit a review

|

(1 Publication)

Rabbit Polyclonal CTAG1B antibody. Suitable for IHC-P and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Synthetic Peptide within Human CTAG1A.

View Alternative Names

CTAG, CTAG1, ESO1, LAGE2, LAGE2A, CTAG1B, LAGE2B, CTAG1A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2, CT6.1, LAGE-2

2 Images

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CTAG1B antibody (AB198878)

IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CTAG1B antibody (AB198878)

Immunohistochemical analysis of paraffin-embedded Human gastric cancer tissue labeling CTAG1B with ab198878 at 1/25 dilution.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CTAG1B antibody (AB198878)

IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CTAG1B antibody (AB198878)

Immunohistochemical analysis of paraffin-embedded Human thyroid cancer tissue labeling CTAG1B with ab198878 at 1/25 dilution.

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

IHC-P

Immunogen

Synthetic Peptide within Human CTAG1A. The exact immunogen used to generate this antibody is proprietary information.

style

left-column

Alternative Products

Primary Antibodies

AB223498

Anti-CTAG1B antibody [SP349]

RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CTAG1B antibody [SP349] (AB223498)

0
0

Primary Antibodies

AB183740

Anti-CTAG1B antibody [EPR13780]

20ul selling size|BOND RX™ Validated|RabMAb|Recombinant|Trial Size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CTAG1B antibody [EPR13780] (AB183740)

3
1

Primary Antibodies

AB242416

Anti-CTAG1B antibody [SP349] - BSA and Azide free

RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CTAG1B antibody [SP349] - BSA and Azide free (AB242416)

0
0

Primary Antibodies

AB139339

Anti-CTAG1B antibody [OTI4D8]

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CTAG1B antibody [OTI4D8] (AB139339)

0
0

Primary Antibodies

AB225536

Anti-CTAG1B antibody [EPR13780] - BSA and Azide free

BOND RX™ Validated|RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CTAG1B antibody [EPR13780] - BSA and Azide free (AB225536)

0
0

Complementary Products

Primary Antibodies

AB237709

Anti-CD8 alpha antibody [CAL66]

BOND RX™ Validated|20ul selling size|RabMAb|Advanced Validation|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD8 alpha antibody [CAL66] (AB237709)

5
2

Primary Antibodies

AB133616

Anti-CD4 antibody [EPR6855]

BOND RX™ Validated|RabMAb|Recombinant|Lab Essentials|20ul selling size|Advanced Validation

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD4 antibody [EPR6855] (AB133616)

5
20

Primary Antibodies

AB52587

Anti-PD1 antibody [NAT105]

BOND RX™ Validated|Recombinant

Immunohistochemistry (Frozen sections) - Anti-PD1 antibody [NAT105] (AB52587)

5
9

Primary Antibodies

AB20034

Anti-FOXP3 antibody [236A/E7]

BOND RX™ Validated|Recombinant|Lab Essentials|Advanced Validation

Multiplex immunohistochemistry - Anti-FOXP3 antibody [236A/E7] (AB20034)

4
38

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/25 - 1/100", "IHCP-species-notes": "<p></p>" } } }

style

left-column

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Immunogen

Storage buffer

pH: 7.4 Preservative: 0.05% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine)

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CTAG1B also known as NY-ESO-1 is a cancer/testis antigen with an approximate molecular mass of 22 kDa. This protein is absent in most normal tissues but shows expression in the testes and a variety of tumors. CTAG1B is recognized for its potential role in immune targeting due to its restricted expression profile. The protein plays a part in antigenic presentation and stimulates T-cell response making it a significant focus for cancer immunotherapy research.

Biological function summary

CTAG1B is involved in the immune response against tumors. It is part of the group called cancer/testis antigens due to its low expression in normal tissues except the testes. This restricted pattern allows CTAG1B to function in distinguishing between tumor and normal cells which is important for targeted therapies. It does not belong to a specific multiprotein complex but contributes to immune recognition by presenting as an antigenic determinant.

Pathways

CTAG1B engages predominantly in cellular processes associated with the immune system's adaptive arm. It plays a role in the antigen processing and presentation pathway where it functions to engage CD8+ T cells. The protein associates with other antigens expressed in cancer such as MAGE-A1 in enabling an immune response against tumor cells. By acting alongside these proteins CTAG1B supports pathways leading to the recognition and destruction of malignant cells.

CTAG1B shows a strong connection to cancer particularly in melanoma and ovarian cancer. It is considered a biomarker for these cancers due to its restricted expression and detection in tumor tissues. In cancer CTAG1B interacts with immune checkpoint proteins such as PD-L1 where it helps sustain and enhance immune responses. This relationship has made CTAG1B a promising target in immunotherapy aiming to improve cancer treatment outcomes.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

See full target information CTAG1A

style

left-column

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Genes, chromosomes & cancer 63:e70007 PubMed39535842

2024

Differential Expression of Proteins and Genes at the Tumor-Brain Interface in Invasive Meningioma.

Applications

Unspecified application

Species

Unspecified reactive species

Kornwika Senglek,Chinachote Teerapakpinyo,Nutchawan Jittapiromsak,Pakrit Jittapiromsak,Irin Lertparinyaphorn,Paul Scott Thorner,Shanop Shuangshoti

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com